Episode Details

In this episode of The BioHub by Avetix, I’m joined by Hans Schambye, CEO of BOOST Pharma.

Hans shares what drew him to BOOST and the opportunity to develop what could become the first disease-modifying treatment for osteogenesis imperfecta. We discuss the challenge of taking a novel cell therapy from early clinical success towards Phase III, and what it takes to build the company around that journey.

We also explore the lessons Hans has learned from leading and scaling multiple biotech companies, how the CEO role changes through different stages of growth, and where he sees the cell and gene therapy landscape heading next.